Agilent Posts Dip in Q3 Bio-Analytical Sales; Will Make Life Sciences Separate Reporting Segment

Beginning with the first quarter of its 2010 fiscal year, Agilent will report Life Sciences as a separate segment due to "explosive growth" in the business. Meanwhile, CEO William Sullivan said he expects the recently launched 1290 Infinity LC System to shift that market to Agilent's favor.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.